Confirmatory Study Nepafenac 0.3%

PHASE3CompletedINTERVENTIONAL
Enrollment

2,120

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

May 31, 2011

Conditions
Cataract
Interventions
DRUG

Nepafenac Ophthalmic Suspension, 0.3%

Nepafenac Ophthalmic Suspension, 0.3%, one drop in affected eye once daily, for 16 days. An additional dose was administered between 30-120 minutes prior to surgery.

DRUG

Nepafenac Ophthalmic Suspension, 0.1%

Nepafenac Ophthalmic Suspension, 0.1%, one drop in affected eye three times daily, for 16 days

OTHER

Nepafenac Ophthalmic Suspension 0.3% Vehicle

Nepafenac 0.3% vehicle, one drop in affected eye once daily, for 16 days. An additional dose was administered between 30-120 minutes prior to surgery.

OTHER

NEVANAC Vehicle

Nepafenac vehicle, one drop in affected eye three times daily, for 16 days

Trial Locations (1)

76134

Contact Alcon Call Center For Trial Locations, Fort Worth

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Alcon Research

INDUSTRY